The term “microbiome” refers to all of the microorganisms (including bacteria, fungi, and other living things) that live inside and on the surface of the human body. There is growing evidence that suggests the microbiome plays a large role in our overall health and wellbeing. However, the relationship between the microbiome and its effect on cancer treatment is not yet known.
This purpose of this study is to investigate the composition of the intestinal microbiome among patients who are receiving immunotherapy treatment for their kidney cancer (i.e. Nivolumab (Opdivo®).
Specifically, the researchers will be focussing on the relationship between a patient’s microbiome and their risk of developing treatment side effects called irAE’s (immune-related adverse events).
Patients in this study will be asked to provide fecal samples at multiple time points during their immunotherapy treatment to evaluate the composition of their intestinal microbiome. No additional visits to the hospital will be needed, as samples will be collected at the time of treatment.
- All subtypes eligible
- Advanced kidney cancer – no curative treatments available
- Must be treated at Princess Margaret Cancer Centre in Toronto
Additional eligibility criteria will apply. Please speak to your doctor.
Find out more about this study.
|Hospital / Cancer Centre||Principal Investigator||Location||Trial Status|
|Hospital / Cancer CentrePrincess Margaret Cancer Centre||Principal InvestigatorDr. Anna Spreafico||LocationToronto, ON||Trial StatusRecruiting|